SiRNA targeting PRK2, which is hepatitis C virus therapeutic agent

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9732346
APP PUB NO 20170002361A1
SERIAL NO

15105516

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to an siRNA targeting PRK2, which is a hepatitis C virus therapeutic agent, and can be effectively used as a hepatitis C virus therapeutic agent since the systemic delivery into a living body, particularly liver cells, is possible through an siRNA targeting a host PRK2 gene, which shows an anti-HCV activity, or a lipid formulation thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
UNIVERSITY-INDUSTRY FOUNDATION YONSEI UNIVERSITY50 YONSEI-RO SEODAEMUN-GU SEOUL 03722

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Oh, Jong-Won Gyeonggi-do, KR 2 0

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Feb 15, 2025
11.5 Year Payment $7400.00 $3700.00 $1850.00 Feb 15, 2029
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00